Private Market View

Jingyang Biotechnology

Guangzhou, China · Founded 2023 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Shenzhen Jiadaogu Investment Management.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Jingyang Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Jingyang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Jingyang Biotechnology

Manufacturer of biopharmaceutical reagents and diagnostic assay solutions aims to support precision healthcare and laboratory innovation. The company's offerings feature advanced molecular diagnostic kits, custom assay development services, and integrated reagent manufacturing capabilities, helping research institutions, clinical laboratories, and biotech firms achieve reliable testing, accurate data, and scalable workflows, enabling efficient deployment of next-generation diagnostic technologies across medical and scientific settings.

Sector
Healthcare
HQ
Guangzhou, China
Founded
2023
Ownership
Privately Held (backing)
PA Mark — not yet priced

Jingyang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Jingyang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Jingyang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.